Literature DB >> 6323678

Evidence for an alpha-1 receptor-mediated central sympathoinhibitory action of ketanserin.

R B McCall, M R Schuette.   

Abstract

The effect of the serotonin receptor antagonist ketanserin on sympathetic nervous discharge recorded from the inferior cardiac and splanchnic nerves was studied in the baroreceptor-denervated cat. Intravenous ketanserin (0.05-0.8 mg/kg) produced dose-dependent decreases in mean arterial pressure, heart rate and sympathetic nervous discharge, with maximal decreases of 41, 7 and 55% of control, respectively. The decrease in mean arterial pressure could not be disassociated from a decrement in the pressor response to i.v. phenylephrine. The central sympatholytic effect of ketanserin was augmented in serotonin-depleted animals. In contrast, the centrally mediated reduction in sympathetic nervous discharge produced by ketanserin was blocked completely in catecholamine-depleted cats. In addition, the central sympatholytic action of the alpha-1 adrenergic receptor antagonist prazosin was blocked in catecholamine-depleted animals. These data indicate that ketanserin acts at central alpha-1 adrenergic receptors to reduce sympathetic outflow from the central nervous system. Central serotonergic pathways do not appear to be involved in the sympatholytic action of ketanserin. The nature of the interaction between central noradrenergic neurons and neurons involved in the genesis of sympathetic nerve activity is discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6323678

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

Review 1.  The role of 5-hydroxytryptamine and 5-hydroxytryptaminergic mechanisms in hypertension.

Authors:  P A van Zwieten; G J Blauw; P van Brummelen
Journal:  Br J Clin Pharmacol       Date:  1990       Impact factor: 4.335

2.  Pharmacological characterization of 5-hydroxytryptamine-induced excitation of afferent cervical vagus nerve in anaesthetized rats.

Authors:  M Yoshioka; T Ikeda; M Abe; H Togashi; M Minami; H Saito
Journal:  Br J Pharmacol       Date:  1992-07       Impact factor: 8.739

3.  Cardiorespiratory effects of a 5HT2 antagonist (R51703) in awake and anesthetized dogs.

Authors:  T J Doherty; W N McDonell; D H Dyson; W D Black
Journal:  Can J Vet Res       Date:  1996-07       Impact factor: 1.310

4.  Mechanisms mediating the ability of caffeine to influence MDMA ('Ecstasy')-induced hyperthermia in rats.

Authors:  N Vanattou-Saïfoudine; R McNamara; A Harkin
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

5.  Inhibitory effect of ketanserin on sympathetic nerve activity in rats.

Authors:  M Yoshioka; M Machiko; H Togashi; M Minami; H Saito
Journal:  Drugs       Date:  1988       Impact factor: 9.546

6.  The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats.

Authors:  Annis O Mechan; Blanca Esteban; Esther O'Shea; J Martin Elliott; M Isabel Colado; A Richard Green
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

7.  Effects of blockade of 5-HT2 receptors and activation of 5-HT1A receptors on the exploratory activity of rats in the elevated plus-maze.

Authors:  V Motta; S Maisonnette; S Morato; P Castrechini; M L Brandão
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

8.  Comparison of ketanserin, buspirone and propranolol on arousal, pupil size and autonomic function in healthy volunteers.

Authors:  Vassilis Koudas; Alexandra Nikolaou; Eugenia Hourdaki; Stella G Giakoumaki; Panos Roussos; Panos Bitsios
Journal:  Psychopharmacology (Berl)       Date:  2009-03-14       Impact factor: 4.530

Review 9.  Serotonin and acute cardiovascular disorders.

Authors:  R S Reneman; P J van der Starre
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

Review 10.  Serotonin and the vascular system. Role in health and disease, and implications for therapy.

Authors:  D S Houston; P M Vanhoutte
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.